NRx Pharmaceuticals, Inc.

NASDAQ:NRXP

Biotechnology

Healthcare
$2.80 +1.43%

+$0.06 today

Market cap
$124.12M
Beta
2.19
P/E (TTM)
-5.3
EPS (TTM)
-$0.76
52W Low $1.62High $5.06

Volume 2.09M

Average 1.27M

NRXP Total Current Assets

All assets expected to be converted to cash or used up within one year.

NRx Pharmaceuticals, Inc.NASDAQ: NRXP

Total Current Assets · Q1 FY2026 · quarter ended Mar 2026

Total current assets broadly unchanged from a year ago

Total current assets stood at $7.36M at the end of Q1 FY2026, up 1.4% from a year earlier and down 17.2% from the prior quarter. Over 3 fiscal years it compounded at -29.9% a year.

Context

  • Total current assets amounted to 61.8% of total assets at the end of Q1 FY2026, down 33.8 pp from a year earlier.
  • Total current assets increased in 1 of the last 3 fiscal years.

What to watch

Whether total current assets keeps rising in the next quarterly balance sheet after a +1.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.36M-17.2% QoQ
Last fiscal yearDec 2025
$8.89M+169.3% YoY
Year agoMar 2025
$7.26M+1.4% since
Total Current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.4%——
1 year+169.3%——
3-year CAGR-29.9%——
5-year CAGR——
10-year CAGR——

Total Current Assets history

USD · from the balance sheet

Latest · FY2025
8.89M USD
Year-over-year change
+169.3%
4-year CAGR
-27.8%

Total Current Assets vs competitors

How NRXP compares with its peers on the latest reported figures

  • NRXP's Mar 2026 total current assets of $7.36M is the 8th highest of the 9 companies compared; the peer median is $40.71M.
  • Its year-over-year change of +1.4% is the 7th highest of 9, against a peer median of +22.2%.
  • Total current assets amounts to 61.8% of total assets for NRXP, versus a peer median of 95.1%.
NRXP Competitors Peer median
Total Current Assets for NRXP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IPSCCentury Therapeutics, Inc.Mar 2026$139.04M -18.0%-27.7%42.6%
KPTIKaryopharm Therapeutics Inc.Mar 2026$126.33M +5.1%-33.5%96.1%
EQEquillium, Inc.Mar 2026$62.28M +284.0%-26.7%98.7%
SPRBSpruce Biosciences, Inc.Mar 2026$55.03M +80.0%-14.6%98.0%
CUECue Biopharma, Inc.Mar 2026$26.39M +65.7%-21.7%85.5%
HOWLWerewolf Therapeutics, Inc.Jun 2026$22.89M -71.5%-25.2%94.8%
OTLKOutlook Therapeutics, Inc.Mar 2026$20.9M +17.4%-14.2%95.5%
NRXPNRx Pharmaceuticals, Inc.Mar 2026$7.36M +1.4%-29.9%61.8%
COEPCoeptis Therapeutics, Inc.Mar 2026$5.91M +27.0%+23.1%29.9%
Peer median (excluding NRXP) $40.71M+22.2%-23.5%95.1%

Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents27.61M20.05M4.6M1.44M7.8M
Short-term Investments00000
Net Receivables07K6K0161K
Inventory00000
Other Current Assets00000
Total Current Assets32.71M25.8M6.88M3.3M8.89M
Property, Plant & Equipment (Net)0000633K
Goodwill00001.79M
Intangible Assets0000925K
Long-term Investments0000397K
Tax Assets00000
Other Non-current Assets15K21K431K349K316K
Total Non-current Assets15K21K431K349K4.06M
Total Assets32.73M25.82M7.32M3.65M12.96M
Account Payables3.69M2.08M4.63M4.13M4.27M
Short-term Debt518K7.7M9.16M1.57M0
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities4.87M37K4.42M10.93M18.31M
Total Current Liabilities11.92M15.59M19.05M21.86M28.58M
Long-term Debt02.82M05.01M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities02.82M05.01M315K
Total Liabilities11.92M18.41M19.05M26.87M28.89M
Common Stock59K67K84K15K32K
Retained Earnings(183.24M)(223M)(253.15M)(278.27M)(306.9M)
Accumulated OCI00(3K)00
Other Stockholders Equity00000
Minority Interest00000
Total Equity20.81M7.41M(11.73M)(23.22M)(15.94M)
Total Debt518K10.53M9.16M6.58M631K
Net Debt(27.09M)(9.53M)4.57M5.13M(7.17M)

NRx Pharmaceuticals, Inc.

NASDAQ:NRXP

Intrinsic Alpha fair value

Locked

Current Price

$2.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.